PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS

摘要

Disclosed are compounds of the formula (I) wherein: R<2>, R<7>, R<13>, R<14> and R15 are independently hydrogen, or (un)substituted lower alkyl, (un)substitued lower alkenyl, (un)substituted lower alkynyl, or (un)substituted -(CH2)nR<12>; R<5> is halogen, cyano, nitro, -R<9>, -NR<9>R<10>, or -OR<9>; R<6> is halogen, cyano, nitro, -R<9>, -NR<9>R<10>, -OR<9>, -Co2R<9>, -COR<9>, -CONR<9>R<10>, -NR<9>COR<10>, (un)substituted lower alkenyl, or (un)substituted lower alkynyl; R<8> is -CO2R<13>, -COR<13>, -CONR<13>R<14>, -CSNR<13>R<14>, -C(NR<13>)NR<14>R<15>, -SO3R<13>, -S02R<13>, -SO2NR<13>R<14>, -PO3R<13>R<14>, -POR<13>R<14>, -PO(NR<13>R<14>)2; R<9> and R<10> are independently hydrogen or (un)substituted lower alkyl; R<11> is a heteroaryl or a heterocyclic group; R<12> is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group; and n is 0,1,2, or 3. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.